Pfizer and Moderna pivotal studies on COVID-19 vaccines near enrollment targets

• COVID-19 vaccine developers Pfizer (PFE +0.6%)/BioNTech SE (BNTX +0.5%) and Moderna (MRNA -2.9%) are closing in on their respective enrollment objectives in their large-scale pivotal studies.
• As of today, Pfizer/BioNTech's 44K-subject Phase 2/3 study evaluating BNT162b2 has enrolled 39,862 participants, 34,601 of which have received the second shot.
• As of Friday, October 16, Moderna has enrolled 29,521 participants in its 30K-subject Phase 3 study of mRNA-1273, 24,496 of which have received the second jab.
• Studies testing AstraZeneca (AZN -0.4%) and Johnson & Johnson's (JNJ -1.1%) candidates, AZD1222 and Ad26.COV2-S, respectively, remain paused while safety signals are investigated.
• Last week, Pfizer chief Albert Bourla said that the company may file its U.S. application for emergency use by late November. It initiated a rolling marketing application in Europe on October 6 and in Canada three days later.
• Moderna launched a rolling marketing application in Canada on October 13.
• Other players: Sanofi (SNY +0.2%), GlaxoSmithKline (GSK -0.3%), Dynavax (DVAX -2.5%), Novavax (NVAX -2.1%), Merck (MRK -0.5%)
• https://seekingalpha.com/news/3623326-pfizer-and-moderna-pivotal-studies-on-covidminus-19-vaccines-near-enrollment-targets